Last reviewed · How we verify
Secretomes
Secretomes is a Biologic drug developed by PT. Prodia Stem Cell Indonesia. It is currently in Phase 1 development.
Researchers at Acorn Biolabs Inc. are studying the use of autologous hair follicle-derived secretome for facial rejuvenation, a treatment also being investigated for other conditions such as polycystic ovary syndrome. The secretome is being tested in a blinded, randomized, controlled trial to evaluate its efficacy and safety.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Secretomes |
|---|---|
| Sponsor | PT. Prodia Stem Cell Indonesia |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Formulation for Improving Vagina Laxity: A Pilot Study (NA)
- Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures
- Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis (PHASE1, PHASE2)
- Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer (PHASE1, PHASE2)
- Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct (PHASE1, PHASE2)
- Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance. (PHASE1, PHASE2)
- Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis (PHASE1, PHASE2)
- Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Secretomes CI brief — competitive landscape report
- Secretomes updates RSS · CI watch RSS
- PT. Prodia Stem Cell Indonesia portfolio CI
Frequently asked questions about Secretomes
What is Secretomes?
Who makes Secretomes?
What development phase is Secretomes in?
Related
- Manufacturer: PT. Prodia Stem Cell Indonesia — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing